english.prescrire.org > Spotlight > Archives : 2011 > In the April issue of Prescrire International : Bradycardia due to cholinesterase inhibitors. Identify adverse effects and take them into account

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

2011 : 1 | 30 | 60

In the April issue of Prescrire International :
Bradycardia due to cholinesterase inhibitors. Identify adverse effects
and take them into account

FREE DOWNLOADWhen an adverse effect has been identified and treated, this information must be shared and taken into account by all those involved in the patient’s subsequent management.
Full text available for free download.

Abstract

  • The cholinesterase inhibitors donepezil, rivastigmine and galantamine have a modest and transient benefit in Alzheimer’s disease. Their known adverse effects include bradycardia.
     
  • A Canadian case-control study conducted between 2003 and 2008 showed a statistically significant increase in the risk of hospitalisation for bradycardia among patients who had been taking a cholinesterase inhibitor for less than 3 months, compared with patients who had stopped taking a cholinesterase inhibitor more than 6 months previously.
     
  • After hospital discharge, more than half of these patients were again prescribed a cholinesterase inhibitor, and 4% of them were re-admitted for bradycardia.
     
  • In practice, when an adverse effect has been identified and treated, this information must be shared and taken into account by all those involved in the patient’s subsequent management. 

Full text available for free download.

©Prescrire 1 April 2011

"Bradycardia due to cholinesterase inhibitors: identify adverse effects and take them into account" Prescrire Int  2011; 20 (115): 95 (Pdf, free).

Download the full review
Pdf, free